Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs GeneDx Holdings Corp — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.72 (market cap $5.86B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 2.9× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and GeneDx Holdings Corp for 19 Days on average.
| JNK | WGS | |
|---|---|---|
Market Cap | $5.86B | $2.02B |
Volume | 7,780,002 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $167.51 |
52-Week Low | $92.30 | $34.51 |
Typical Hold Time | 61 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK, a high-yield bond ETF, trades at $92.83, up 0.08% on the day, amid a bearish technical signal from moving averages. The fund maintains a consistent dividend payout, with recent distributions of $0.53. Market sentiment is influenced by rising bond yields and geopolitical tensions, as highlighted in recent financial news.
The outlook for JNK is challenged by high interest rates and inflation concerns, which pressure junk bond valuations. Opportunities exist for income-focused investors due to the ETF's yield, but risks include further yield spikes and economic slowdowns affecting credit quality.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
